Saint Mary's Healthcare Standardizes on Industry-Leading Masimo
SET® Pulse Oximetry
AMSTERDAM, NEW YORK and
IRVINE, Calif., Nov. 29, 2012 /PRNewswire/ -- Saint
Mary's Healthcare, the first hospital in New York State to achieve the "Pathway to
Excellence" Designation from the American Nurses Credentialing
Center, and Masimo (NASDAQ: MASI) today jointly announce that Saint
Mary's has standardized to Masimo SET® Measure-Through
Motion and Low Perfusion pulse oximetry, the standard-of-care at
leading hospitals worldwide.
Standardizing to Masimo SET® allows clinicians to
accurately monitor blood oxygen saturation in challenging
conditions – establishing the technology as an industry-leading
pulse oximetry that substantially contributes to improved patient
outcomes.
"The one thing I really appreciate about Masimo's technology is
that we've been able to get dependable, reliable readings on
neonates," said Rob Noel, Senior
Respiratory Therapist at Saint Mary's Healthcare. "We're getting
more readings than we were before, especially when movement is
involved. When we put this technology on newborns, we know we're
getting the right information."
In addition to Masimo SET®, which virtually
eliminates false alarms1 and increases a clinician's
ability to detect life-threatening events,2 Saint Mary's
will benefit from breakthrough rainbow® technology that
allows clinicians to measure multiple blood constituents, fluid
responsiveness, respiration rate, and other physiological
parameters noninvasively and continuously. Parameters at Saint
Mary's include total hemoglobin (SpHb®), and
carboxyhemoglobin (SpCO®), as well as the
Measure-Through Motion and Low Perfusion performance of Masimo
SET® oxyhemoglobin (SpO2), perfusion index
(PI), and pulse rate (PR).
Saint Mary's will deploy SpHb in its emergency department.
Masimo SpHb enables clinicians to measure hemoglobin and trending
noninvasively and continuously.3 A recent study also
noted that, "Because SpHb measurement is noninvasive, it has the
potential to confer the additional benefits of patient comfort,
decreased complexity, and increased safety for health care
providers who are not exposed to risks of needle-stick injury and
blood-spill contaminations."4 Likewise, SpCO
allows clinicians to noninvasively and quickly detect elevated
levels of carbon monoxide in the blood – facilitating earlier
diagnosis and treatment.5
According to Peter Holtermann,
Director of Medical Imaging at Saint Mary's, "The true benefit of
the standardized equipment is to the patient. The accuracy of the
testing and its less invasive nature enable patients to receive
care that is less painful and more timely."
"We are happy to have this partnership with Saint Mary's, which
like other great healthcare organizations is demonstrating its
commitment to patient safety and care by taking advantage of our
breakthrough patient monitoring technologies such as SpHb – a
continuous noninvasive way to measure total hemoglobin, and our
measure-through motion and low perfusion pulse oximetry technology,
which has been proven to improve care and reduce costs," said
Masimo founder and CEO Joe Kiani.
"Together, we look forward to helping Saint Mary's meet and exceed
its patient-care needs."
1 Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of
three new-generation pulse oximeters during motion and low
perfusion in volunteers." Journal of Clinical
Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available
online here
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike,
George T. "Impact of Pulse Oximetry Surveillance on Rescue Events
and Intensive Care Unit Transfers: A Before-and-After Concurrence
Study." Anesthesiology, February
2010, Vol. 112, Issue 2. Available
online here
3 Frasca D., Dahyot-Fizelier C., Catherine K., Levrat Q., Debaene
B., Mimoz O. "Accuracy of a Continuous Noninvasive Hemoglobin
Monitor in Intensive Care Unit Patients."Crit Care Med. 2011
Oct;39(10):2277-82. Available online here.
4 Raikhel M. "Accuracy of Noninvasive and Invasive Point-of-Care
Total Blood Hemoglobin Measurement in an Outpatient Setting"
Postgraduate Medicine, Volume 124, Issue 4, July 2012, ISSN – 0032-5481, e-ISSN –
1941-9260.
5 Hampson N. "Noninvasive pulse CO-oximetry expedites evaluation
and management of patients with carbon monoxide poisoning." The
American Journal of Emergency Medicine 2012
(10.1016/j.ajem.2012.03.026) Available online here
About Saint Mary's Healthcare
St. Mary's Healthcare is
a continuum of health care services offering a comprehensive
network of high quality, local, compassionate care. Services
include but are not limited to 120 acute care beds, 10 primary and
specialty care centers in Fulton
and Montgomery counties, more than
30 behavioral health services in Fulton, Montgomery and Hamilton counties, a 10 bed Acute Inpatient
Rehabilitation Unit, a 10 bed Transitional Care Unit, and a 160-bed
nursing home. St. Mary's received 5-star ratings from HealthGrades
for four consecutive years and in 2011 became the first hospital in
New York State to achieve the
"Pathway to Excellence" Designation. Our 1600+ associates embrace
the mission of providing every individual with an exceptional
patient experience. Founded by the Sisters of St. Joseph of
Carondelet in 1903, and as a member of Ascension Health since 2002,
St. Mary's is dedicated to improving the health of the community
with special attention to the poor and underserved. Please visit
www.smha.org.
About Masimo
Masimo (NASDAQ: MASI) is the global
leader in innovative noninvasive monitoring technologies that
significantly improve patient care—helping solve "unsolvable"
problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®,
which virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. More than 100
independent and objective studies have shown that Masimo
SET® outperforms other pulse oximetry technologies, even
under the most challenging clinical conditions, including patient
motion and low peripheral perfusion. In 2005, Masimo introduced
rainbow SET® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously required invasive procedures, including total hemoglobin
(SpHb®), oxygen content (SpOCTM),
carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), and Pleth Variability Index (PVI®),
in addition to SpO2, pulse rate, and perfusion index
(PI). Additional information about Masimo and its products may be
found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb) and SpCO
contribute to positive clinical outcomes and patient safety under
all circumstances; risks related to our belief that Masimo
noninvasive medical breakthroughs provide solutions with comparable
accuracy and unique advantages, including: immediate and continuous
results that enable earlier treatment without causing invasive
trauma in all patients and in every clinical situation; as well as
other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website
at www.sec.gov. Although we believe that the expectations reflected
in our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified
in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not
undertake any obligation to update, amend or clarify these
forward-looking statements or the "Risk Factors" contained in our
most recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required
under the applicable securities laws.
Media
Contacts:
|
|
Jerri
Cortese
|
Mike
Drummond
|
Saint
Mary's Healthcare
|
Masimo
Corporation
|
Phone:
(518) 841-7162
|
Phone:
(949) 297-7434
|
Email:
cortesej@smha.org
|
Email:
mdrummond@masimo.com
|
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care... by Taking Noninvasive
Monitoring to New Sites and Applications, rainbow, SpHb, SpOC,
SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7,
Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter,
Adaptive Threshold Alarm, and SEDLine are trademarks or registered
trademarks of Masimo Corporation. The use of the trademarks Patient
SafetyNet and PSN is under license from University HealthSystem
Consortium.
SOURCE Masimo